How Much is Enough? Impact of Efflux Transporters on Drug delivery Leading to Efficacy in the Treatment of Brain Tumors
Open accessThe DOI matches its Crossref record; 119 of the 119 references it cites were found in a registry or an index.
Abstract
The lack of effective chemotherapeutic agents for the treatment of brain tumors is a serious unmet medical need. This can be attributed, in part, to inadequate delivery through the blood-brain barrier (BBB) and the tumor-cell barrier, both of which have active efflux transporters that can restrict the transport of many potentially effective agents for both primary and metastatic brain tumors. This review briefly summarizes the components and function of the normal BBB with respect to drug penetration into the brain and the alterations in the BBB due to brain tumor that could influence drug delivery. Depending on what is rate-limiting a compound's distribution, the limited permeability across the BBB and the subsequent delivery into the tumor cell can be greatly influenced by efflux transporters and these are discussed in some detail. Given these complexities, it is necessary to quantify the extent of brain distribution of the active (unbound) drug to compare across compounds and to inform potential for use against brain tumors. In this regard, the metric, Kp,uu, a brain-to-plasma unbound partition coefficient, is examined and its current use is discussed. However, the extent of active drug delivery is not the only determinant of effective therapy. In addition to Kp,uu, drug potency is an important parameter that should be considered alongside drug delivery in drug discovery and development processes. In other words, to answer the question - How much is enough? - one must consider how much can be delivered with how much needs to be delivered.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Drug efflux pumps active within brain capillary endothelial cells further limit the delivery of MDM2 inhibitors into tumor regions with a relatively intact BBB.17 , 26”
From Pharmacokinetic-pharmacodynamic-efficacy modeling of the MDM2 inhibitor brigimadlin in glioblastoma patient-derived xenografts (2026) · cites this paper as [26]
The cited source says what the claim attributes to it.
In the citing paper
“Additionally, the expression of the P-gp efflux transporter is approximately two- to fourfold higher in mice than in humans (41).”
From Preclinical Modeling of Navtemadlin Pharmacokinetics, Pharmacodynamics, and Efficacy in IDH–Wild-type Glioblastoma (2025) · cites this paper as [41]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Radiotherapy Plus Concomitant and Adjuvant Temozolomide for Glioblastoma
Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J. B., Belanger, K., Brandes, A. A., Marosi, C., Bogdahn, U., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa043330 · Cited by 21,807
Siegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Stupp, R., Hegi, M. E., Mason, W. P., van den Bent, M. J., Taphoorn, M. J., Janzer, R. C., Ludwin, S. K., Allgeier, A., Fisher, B., Belanger, K., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70025-7 · Cited by 7,668 · cited 1×
“…properties – small size (MW = 194.15 g/ mol) and hydrophilic/lipophilic balance (logP = -1.153), TMZ penetrates the BBB relatively well, at least well “enough” to improve the median survival of GBM patients by 2.5 months (14.6 vs. 12.1 months) compared to the placebo treatment [113].”
InfluentialVogelstein, B., Lane, D., & Levine, A. J. (2000) · Nature · doi:10.1038/35042675 · Cited by 6,607
The DNA-damage response in human biology and disease
Jackson, S. P., & Bartek, J. (2009) · Nature · doi:10.1038/nature08467 · Cited by 6,092 · cited 2×
“…mutated kinase (ATM), ataxia telangiectasia and Rad3 related protein kinase (ATR), poly (ADP-ribose) polymerases (PARP), and DNA-dependent protein kinase (DNA-PK), in combination with radiation and/or chemotherapeutic agents, has great potential to improve the tumor treatment efficacy [118, 119].”
Immunotherapy of Diffuse Gliomas: Biological Background, Current Status and Future Developments
Grauer, O. M., Wesseling, P., & Adema, G. J. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00315.x · Cited by 4,007
A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants
Juliano, R. L., & Ling, V. (1976) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/0005-2736(76)90160-7 · Cited by 3,296 · cited 1×
“The “P” was designated for its influence on drug permeability [55].”
Overexpression of a Transporter Gene in a Multidrug-Resistant Human Lung Cancer Cell Line
Cole, S. P. C., Bhardwaj, G., Gerlach, J. H., Mackie, J. E., Grant, C. E., Almquist, K. C., Stewart, A. J., Kurz, E. U., Duncan, A. M. V., & Deeley, R. G. (1992) · Science · doi:10.1126/science.1360704 · Cited by 3,037 · cited 1×
“The multidrug resistance-associated protein (MRPs, ABCC) family has multiple members, of which MRP1 was the first ABC transporter involved in multidrug resistance identified in a multidrug-resistant human lung cancer cell line [64, 65].”
Srimaroeng, C., Cecile, J. P., Walden, R., & Pritchard, J. B. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350077 · Cited by 2,989
The Neurovascular Unit Coming of Age: A Journey through Neurovascular Coupling in Health and Disease
Iadecola, C. (2017) · Neuron · doi:10.1016/j.neuron.2017.07.030 · Cited by 2,480 · cited 1×
“These cells, together with other essential cell types such as microglia and neurons, form the neurovascular unit (NVU) [22].”
Research works printed but not linked: 3
- Arvanitis CD, Ferraro GB, Jain RK. The blood–brain barrier and blood–tumour barrier in brain tumours and metastases. Nat Rev Cancer. 2020;20:26–41. · DOI · Paper page
- Talele S, Zhang W, Burgenske DM, Kim M, Mohammad AS, Dragojevic S, et al. Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma. J Pharmacol Exp Ther. 2021;379:343 LP – 357. · DOI
- Gampa G, Kim M, Cook-Rostie N, Laramy JK, Sarkaria JN, Paradiso L, et al. Brain Distribution of a Novel MEK Inhibitor E6201: Implications in the Treatment of Melanoma Brain Metastases. Drug Metab Dispos United States. 2018;46:658–66. · DOI
Cited by
Oh, J., Reed, S. K., Riviere-Cazaux, C., Kim, M., Mladek, A. C., Illamola, S. M., Zhang, W., Vaubel, R. A., Caron, A. A., Regan, M. S., et al. (2025) · Neuro-Oncology · doi:10.1093/neuonc/noaf204 · Cited by 18
Self-citationDeciphering the Blood–Brain Barrier Paradox in Brain Metastasis Development and Therapy
Peters, J. J., Teng, C., Peng, K., & Li, X. (2025) · Cancers · doi:10.3390/cancers17020298 · Cited by 16
Yang, J., Huang, E. P., Liao, K. Y.-K., BAU, D.-T., Tsai, S.-C., Chen, C., Chen, K., Liu, T.-Y., Chiu, Y.-J., & Tsai, F. (2024) · Biomedicine · doi:10.37796/2211-8039.1474 · Cited by 11
“Candidates that can cross the BBB usually have certain traits: they are very attracted to fats, have a low molecular mass (usually less than 400 e 600 Da), do not bind well to plasma proteins very well, and do not break apart easily at physiological pH condition [6,7].”
Jian-fen, W., Wu, H., Zhou, F., Wang, Y., Wang, C., & Ji, J. (2025) · Cancer Gene Therapy · doi:10.1038/s41417-025-00916-6 · Cited by 10
“The BTB harbors considerable structural and functional heterogeneity and is characterized by numerous distinct features, including non-uniform permeability and active ef fl ux of molecules [85].”
Daškevičiūtė, A., Zaboras, E., Navalinskas, J., Baronas, K., Jasionis, A., Navickienė, E., & Mameniškienė, R. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26125548 · Cited by 7
“They include ATP-binding cassette transporters, especially P-glycoprotein (P-gp, ATP-Binding Cassette Subfamily B Member 1 [ABCB1]), multidrug resistance-associated proteins (MRPs, ABCC), and breast cancer resistance proteins (BRCP, ABCG2) [6].”
Metadata
- Authors
- Zhang, W., Oh, J.-H., Zhang, W., Rathi, S., Le, J., Talele, S., Sarkaria, J. N., & Elmquist, W. F.
- Affiliations
- University of Minnesota (US)
- Mayo Clinic (US)
- Corresponding author
- Elmquist, William F.
- ORCID
- Venue
- Pharmaceutical Research
- Published
- 2023-08-17
- Volume
- 40
- Issue
- 11
- Pages
- 2731-2746
- ISSN
- 0724-8741 (ISSN-L)
- 1573-904X
- PMC
- PMC10841221
- OpenAlex
- W4385898121
- Cited by
- 19
- References
- 119
- Citations by year
- 2026: 7 · 2025: 8 · 2024: 4
- FWCI
- 0.62
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Pharmaceutical Research (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Foundation for the National Institutes of Health (U19-CA264362, U01-CA227954)
- National Brain Tumor Society (AWD0006946 / 21-004061)
- Topics
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Neuroscience › Neurology › Barrier Structure and Function Studies
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- efflux pumps, brain tumors, blood-brain barrier, drug delivery, drug penetration, brain distribution, drug potency, anticancer agents, brain metastases
- MeSH terms
- Biological Transport, Blood-Brain Barrier, Brain, Brain Neoplasms, Pharmaceutical Preparations, Humans, Membrane Transport Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: How Much is Enough? Impact of Efflux Transporters on Drug delivery Leading to Efficacy in the Treatment of Brain Tumors. https://app.cochat.ai/papers/10.1007/s11095-023-03574-1
- The paper
- Zhang, W., Oh, J.-H., Zhang, W., Rathi, S., Le, J., Talele, S., Sarkaria, J. N., & Elmquist, W. F. (2023). How Much is Enough? Impact of Efflux Transporters on Drug delivery Leading to Efficacy in the Treatment of Brain Tumors. Pharmaceutical Research. https://doi.org/10.1007/s11095-023-03574-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.